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Purpose: Newborn bloodspot screening (NBS) programs have expanded significantly in 
the past years and are expected to expand further with the emergence of genetic tech-
nologies. Historically, NBS expansion has often occurred following ad hoc consideration 
of conditions, instead of a structured and transparent approach. In this review, we explore 
issues pertinent to NBS policy making, through the lens of the policy cycle: (a) agenda 
setting, (b) policy advice, (c) policy decision, (d) implementation, and (e) evaluation.
Methods: A literature search was conducted to gather information on the elements 
specific to NBS and its policy making process.
Results: The review highlighted two approaches to nominate a condition: a structured 
approach through horizon scanning; and an ad hoc process. For assessment of a 
condition, there was unanimous support for a robust process based on criteria. While 
the need to assess harms and benefits was a repeated theme in the articles, there 
is no agreed-upon threshold for benefit in decision-making. Furthermore, the literature 
was consistent in its recommendation for an overarching, independent, multidisciplinary 
group providing recommendations to government. An implementation plan focusing on 
the different levels on which NBS operates and the information needed on each level 
is essential for successful implementation. Continuously monitoring, and improving a 
program is vital, particularly following the implementation of screening for a new con-
dition. An advisory committee could advise on implementation, development, review, 
modification, and cessation of (parts of) NBS.
Conclusion: The results highlight that there are a wave of issues facing NBS programs 
that policy makers must take into account when developing policy processes. What 
conditions to screen, and the technologies used in NBS, are both up for debate.
Keywords: decision making, newborn screening, public health policy, genomic screening, genetic testing
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inTRODUCTiOn
Newborn bloodspot screening (NBS) is the longest running 
and most successful population screening program worldwide 
(1). NBS tests newborns within the first days of life for multiple 
serious conditions (2). The traditional aim of NBS is to prevent 
serious consequences for the newborn by enabling timely 
diagnoses and treatment for early onset childhood conditions 
(3). In recent years, technological developments, changes in 
understanding of conditions, and new treatments, have fueled 
the expansion of NBS (4, 5). The aim of this study is to explore 
issues influencing each phase of the policy cycle. In doing so, this 
study provides policy makers insight in the pressures facing NBS 
to inform them on approaches to successfully guide programs 
into the future.
An archetypal example of the policy pressures facing NBS 
was the advent of tandem mass spectrometry (MS/MS), and 
the resultant impact it had upon programs worldwide. This 
technology emerged in the 1990s and made it possible to test 
for several conditions at once in a cost-effective manner (4, 5). 
Correspondingly, several programs adopted the technology 
and significantly increased the number of conditions screened. 
Programs using these technologies regularly screen from 9 to 
over 50 conditions (1, 6–9). Even more than MS/MS, genetic 
technologies may enable screening for a larger number of condi-
tions (3, 10, 11). Debate abounds in the academic literature on 
the appropriateness of expanding NBS (4, 10, 12): some authors 
advocate for targeted approaches (13, 14); while elsewhere next 
generation sequencing is being applied in the research setting to 
study it’s potential for NBS (15, 16).
Previous expansions and the divergent programs that have 
evolved, suggest that the emergence of genetic technologies is 
likely to be a significant turning point for NBS. Given the reach 
of NBS, that NBS tests our most vulnerable population, and the 
potential to increasingly expand programs, it is essential that 
decisions on what to screen are carefully considered. Thus policy 
approaches are needed which can successfully navigate in the 
changing environment (14). It can be expected that an expansion 
occurring in some countries will become an example of what is 
possible for other countries (17). At a minimum, further debate 
will emerge on the pros and cons of expanded screening, and 
experts, consumers, and advocacy groups are likely to increase 
calls for screening for specific conditions (17). The emergence 
of debates on further expanding NBS presents decision makers 
worldwide with the challenge of weighing the benefits and harms 
of screening in the changing landscape of NBS. Policy frame-
works, which are developed in light of the range of policy issues, 
will be essential for policy makers to ensure their programs can 
effectively respond to the pressures facing the program, now and 
in the future.
Given the pressures for NBS, the current study aims to iden-
tify what the scientific literature outlines are the key policy con-
siderations currently facing NBS. This is achieved by exploring 
issues pertinent to NBS policy making, through the lens of the 
policy cycle (10): (a) agenda setting, (b) policy advice, (c) policy 
decision, (d) implementation, and (e) evaluation. Without 
detailing current developments in genomic technologies, we 
aim to explore issues influencing each phase of the policy cycle. 
In doing so, this study will enable policy makers responsible for 
existing or emerging NBS programs to consider the best policy 
structure to respond to the changing environment in which 
NBS operates.
MeTHODS
We explored academic literature to summarize relevant fac-
tors pertinent to policy making for NBS. International policy 
making processes have been recently reviewed elsewhere (1, 
12). The current study builds upon what is known about the 
tangible policy making process, by highlighting issues facing 
NBS identified in academic literature. This then provides policy 
makers an outline of the issues that should be considered in 
the development of policies. To be included in the review an 
article needed to discuss one or more of the following topics: 
nomination of a condition (agenda setting); consideration of 
a condition (policy advice); deciding on a condition (policy 
decision); addition of a condition (implementation); or quality 
assurance and improvement (evaluation). Articles were also 
included if they discussed all elements of the policy cycle, such 
as mention of a comprehensive policy framework for NBS 
policy making.
We searched PubMed for articles regarding newborn screening 
and policy. We combined the two key search terms with the fol-
lowing search terms: 1. program development, 2. decision-making, 
3. governance, 4. management, 5. perspective, 6. future, and 7. 
disease or condition. Only English publications on dried bloods-
pot screening were included. Articles concerning other types of 
newborn screening (e.g., hearing, hip dysplasia) were excluded, 
because we wanted to focus on the complex policy making spe-
cific to bloodspot screening.
ReSULTS
The initial literature search identified 59 articles. Twenty-seven 
articles discussed one or more of the elements of the policy cycle 
(Table S1 in Supplementary Material). Most literature originated 
from western societies, predominantly the USA (13 of 27 articles, 
Table S1 in Supplementary Material) and was initiated from a 
clinical background rather than a public health background 
(Figure S1 in Supplementary Material). The main technology 
discussed in the articles shows a shift through time from MS/MS 
toward discussing genetic technologies as the challenge for NBS: 3 
of 13 articles until 2008 discuss mainly genetic technologies and 6 
of 14 published since 2009 (Table S1 in Supplementary Material). 
Recent articles discussing MS/MS report on results from current 
screening programs or previous decision-making processes (18). 
The following outlines the results, stepping through the policy 
cycle.
Agenda Setting: nominating a Condition
The review highlighted two approaches to nominating a condition. 
The first is a structured approach focused on horizon scanning; 
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the second approach is much more ad  hoc and influenced by 
external drivers, such as advocacy (18–20).
The structured, horizon scanning approach generally includes 
an independent body that undertakes horizon scanning to 
identify a range of relevant conditions to evaluate for NBS and 
support expansion through an evidence-based process (10, 21, 
22). Such an approach has been successfully used by several 
countries in agenda setting based on an objective threshold 
of criteria (18, 22). In horizon scanning, potential conditions 
are identified and recommended for further in-depth review, 
through initial assessment of criteria. Contrary to the organized 
horizon scanning approach, the majority of the literature focused 
on an ad hoc approach. In this approach, conditions became the 
focus of an assessment for NBS in response to new technologies, 
broader disease definition, insight into pathophysiology, and 
advocacy (5, 23–26). In the past, NBS policy direction and pro-
gram expansion have been strongly influenced by technological 
drivers, often evaluated ad hoc (18–20).
Advocacy is a key driver for change within NBS. Pressure by 
consumers, clinicians, and scientists to screen for a condition dates 
back to the very first condition screened in NBS, phenylketonuria 
(PKU). NBS for PKU was advocated by Dr Guthrie, whose son 
was born mentally handicapped and whose niece experienced 
intellectual disability due to undiagnosed and unmanaged PKU 
(5). Dr Guthrie developed a test to identify the condition and 
advocated for mass screening of PKU through community sup-
port groups (5). Recent examples of advocate pressure leading to 
the introduction of a condition include in the instance of X-linked 
adrenoleukodystrophy and Krabbe disease in the USA (5, 10, 27). 
However, the benefits of screening, for Krabbe are disputed in 
literature and referred to as “dangerous and expensive” (27).
Policy Advice: Assessment of a Condition
Within the literature reviewed, there was unanimous support 
for a robust assessment process based on criteria. However, a 
key issue relating to the assessment of nominated conditions 
centered on the appropriateness of using criteria originating 
from the Wilson and Jungner principles (10, 28, 29). Criticisms 
are voiced that the Wilson and Jungner principles are developed 
to evaluate individual conditions, while modern day technology 
pushes toward the possibility and sometimes the need to evaluate 
groups of conditions at once (30, 31). Furthermore, there is no 
objective tool developed from the Wilson and Jungner principles, 
which leaves them open to interpretation into different criteria 
between programs (31).
While the need to assess harms and benefits was a repeated 
theme in the articles, there is no agreed-upon threshold for 
benefit (10, 22, 29). This is essential to effectively explore the 
benefits and harms of screening, to ensure that the former 
outweighs the latter. The benefit of screening is intrinsically 
related to the primary aim of screening, which is predomi-
nantly to avoid preventable harm in newborns. The aim and 
beneficiary screening should both be specified in policies, as 
they are open to interpretation (9, 32, 33). That is, to support 
assessing the appropriateness of a condition, there needs to a 
clear understanding of who will benefit from screening, what is 
the perceived benefit, and how should it be weighed in decisions 
(10, 22). In general, three groups were mentioned as potential 
beneficiaries of NBS: the child, the family, and/or society (34). 
In the recent report from the Health Council of the Netherlands, 
the beneficiary of screening was specifically defined as the child. 
Consequently, this lead to conditions without clear clinical 
benefits to the child to be assessed as inappropriate for inclusion 
within NBS (12).
Policy Decision: Deciding on a Condition
The literature focused on two key areas when deciding whether 
to screen a condition. The first focused on who makes the 
decision, and the second focused on the evidence on which 
the decision is made. The literature was consistent in its 
recommendation for an overarching, independent, multidis-
ciplinary group providing recommendations to government 
(18, 24, 28).
In terms of evidence, authors of the reviewed literature 
identified that decisions in NBS often need to be made based 
on incomplete information (22). A main concern identified in 
several articles, is the lack of data to support evidence-based 
decisions. There is the need for interoperable databases to col-
lect sufficient data on the diseases considered and included in 
NBS (10, 23, 35). Alternatively, authors suggested that innova-
tions in NBS should be implemented in a research paradigm, to 
facilitate data collection for policy decisions, and gain informed 
consent from parents participating with their child(ren) in the 
study (22, 30, 33, 35). Pilot studies are vital to the development 
of a strong evidence base to support decision-making regard-
ing the addition of new conditions. As shown in Denmark, the 
Faroe Island, and Greenland, a pilot program of 7 years eventu-
ally provided information for evaluation and the subsequent 
decision to not include 11 conditions in the routine screening 
program in 2009 (36).
implementation: Addition of a Condition
Once a condition is approved for implementation in a NBS pro-
gram, an implementation plan focusing on the different levels 
on which NBS operates and the information needed at each 
level should be developed (21, 37, 38). Issues across programs 
are similar when looking at implementation and relate to five 
fields: education, finances, logistics, politics, and culture (5, 
24). These fields extend beyond “public health” to also include 
follow-up in the clinical setting. Key issues include the need for 
work flow across these fields to be coordinated, and ensuring 
professionals have the relevant skills and knowledge for the new 
condition(s) (24, 39). Issues to ensure skills and knowledge are 
particularly challenging where conditions are being identified in 
the pre-symptomatic phase, and there may be a lack of evidence 
or consensus in clinical guidelines. This will be further chal-
lenged if the preferred technology moves toward genome-based 
technologies, which can identify genetic variations that have 
implications for family members. These technologies will lead to 
issues relating to privacy and confidentiality, residual specimen 
storage and usage policies, and educational material to become 
even more pressing (40).
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evaluation: Quality Assurance and 
improvement
Continuously monitoring, and improving a program is vital, 
particularly following the implementation of screening for a new 
condition (30). It is possible that a condition assessed as being 
appropriate to screen, will not meet the parameters upon which 
this decision was based. For example, the false positives or nega-
tives recorded for a test within a trial period might not align with 
those that occur in the real world setting. Thus quality assurance 
(QA) is required to monitor the program’s performance against 
defined targets to ensure it aligns with the anticipated outcomes 
(22, 29, 34).
QA provides essential ongoing assessment of feasibility, cost, 
and equitable delivery of testing (10, 32, 37). Some authors sug-
gest principles for QA, such as clear guidelines on responsibilities 
throughout the chain of NBS; standards on aspects regarding 
confidentiality; and protocols for storage of blood spot speci-
mens (21). Importantly, QA should be complemented by quality 
improvement (QI). QI builds upon QA, to drive improvements 
and achieve success. Issues for QI within NBS include managing 
the improvement process across the NBS system: from health-
care professionals to laboratory experts. Ways to overcome 
fragmentation of providing information on the key indicators 
while gaining data on them from all parts of NBS can be provid-
ing training, develop written educational materials for parents 
and health-care professionals, and redesign laboratory slips for 
blood collection (21).
Policy Cycle in General
Authors advocated a transparent, structured, and evidence-
based process (22, 25, 41). Policy making for NBS can be 
governed both locally and nationally (38, 42). Governance is 
a process that focuses on balancing competing influences and 
demands (43). The need for harmonization of national policies 
is often referred to in literature: to ensure a national balance in 
competing interests and equity in access to early interventions 
(29, 31). A central body like a national or federal government 
should play a core role in overseeing NBS. In addition, consulta-
tion and engagement is a key theme, which some authors high-
light should be managed through a multidisciplinary advisory 
committee providing advice through the policy cycle (28). An 
advisory committee could advise them on implementation, 
development, review, modification, and cessation of (parts of) 
NBS (21, 29, 38).
DiSCUSSiOn
Stepping through the policy cycle illustrated that NBS is on 
the precipice of great change. Programs are facing a wave of 
pressures, including in response to new treatments and new 
technologies. The history of NBS suggests the programs are 
flexible in responding to a continually changing environment. 
However, the historical ad hoc approach to adding conditions 
to NBS is recognized as potentially problematic in the light of 
future developments. Current NBS programs might contain 
conditions that have not been robustly evaluated through an 
agreed policy advice process. Future developments and chal-
lenges highlight that policy makers need to take stock of the 
issues facing the programs, and develop policies that will ensure 
safe and appropriate growth of programs (22, 25, 41).
The growing number of conditions that could be screened is 
a key issue for NBS programs, particularly in the face of pres-
sures from next generation sequencing (13, 44). Moreover, the 
potentially growing number of conditions extends beyond what 
is technologically possible, to challenge the fundamental pur-
pose of the programs. Internationally, there are increasing calls 
to move further beyond the traditional aim of NBS, and screen 
for “untreatable” conditions (33, 34). Untreatable conditions 
do not always have a certain treatment benefit or treatment is 
not urgently needed in the newborn period. For untreatable 
conditions to be implemented in NBS, some argue that the 
aim has to shift from clinical benefits solely for the child, to 
include family benefits (24, 29). Such a shift in the focus of 
beneficiary beyond the newborn, will lead to a vast increase in 
the number and type of conditions eligible for screening (3, 22): 
a great number of conditions may have family benefit through 
information on relevant reproductive options compared to a 
limited amount of conditions that have direct clinical benefit 
for the newborn (34).
The above issues overwhelmingly outline the need for robust 
and considered policy making for NBS. However, it is unclear 
whether such policy making can fully combat the pressures 
facing the program. Many nomination processes can still be 
considered passive where a nomination is awaited, instead of 
active horizon scanning for relevant conditions. Further, should 
there be a shift in focus or a push for more conditions to be 
screened, it is recommended that this be accompanied with 
consideration as to whether NBS is the right place to screen for 
such conditions. Specifically, in order to protect the programs 
and ensure they stay true to their aim, consideration should 
be given to preconception, prenatal, or screening during early 
childhood.
Our study has several limitations, data from the USA were 
overrepresented (13 of the 27 articles) and a sample of 27 articles 
might not be representative for international policy making in 
NBS. Further, the policy cycle is theoretical. As such, the recom-
mendations from academic literature are prone to interpretational 
disparity between theory and practice. Nonetheless, this review 
shows relevant aspects in policy making and addresses gaps in the 
current processes. Our results suggests that there is the need for 
a structured and timely approach that responds to the changing 
environment.
Through a systematic, continuous policy process, NBS pro-
grams will be able to anticipate developments, as opposed to 
being reactive and heavily influenced by external drivers. A policy 
process that is developed in light of the issues raised here will help 
the programs to anticipate challenges and progress in a safe and 
effective way. A framework to facilitate this approach should be 
strived for. Only by making careful and considered decisions, can 
we ensure that NBS of the future is as successful as the existing 
programs we know today.
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